Dublin, Oct. 12, 2018 (GLOBE NEWSWIRE) -- The "Wearable Injectors Market by Type (On-Body and Off-Body injectors (Infusion Pump Devices)), Therapy (Immuno-oncology, Diabetes, Cardiovascular Diseases, Parkinson's Disease, Thalassemia, Primary Immunodeficiency Disease) - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering.

The global wearable injectors market is projected to reach USD 9.41 billion by 2023 from an estimated USD 5.57 billion in 2018, at a CAGR of 11.1% during the forecast period.

The growing prevalence of targeted therapies, favorable reimbursement, and technological advancements in wearable injectors are expected to drive the growth of the wearable injectors market. However, the preference for alternative routes of drug delivery such as pens & autoinjectors is expected to restrain the growth of this market to a certain extent.

Based on type, the market is segmented into on-body and off-body injectors. The off-body injectors segment is expected to register the highest CAGR during the forecast period. The drawbacks associated with on-body wearable injectors, such as painful removal, skin sensitivity issues and irritation, and adhesive fitting issues have resulted in the increased demand for off-body injectors.

Based on therapy, the global wearable injectors market is segmented into immuno-oncology, diabetes, cardiovascular diseases, and other therapies (Parkinson's Disease, thalassemia, and primary immunodeficiency disorders).

The cardiovascular diseases segment is expected to witness the highest CAGR during the forecast period. The high growth of the segment can be primarily attributed to the high burden of CVDs across the globe coupled with the growing availability of wearable injectors for the treatment of CVDs.

North America is expected to witness the highest growth from 2018 to 2023. This can be attributed to the rising prevalence of chronic diseases in the US and Canada; favorable reimbursement scenarios; and an increasing number of awareness programs in the US and Canada.

The report analyzes the wearable injectors market and aims at estimating the market size and future growth potential of this market based on various segments such as type, therapy, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Premium Insights
4.1 Wearable Injectors Market: Overview
4.2 Global Market, By Type, 2018 vs 2023
4.3 Geographic Analysis: Global Market, By Therapy
4.4 Geographic Snapshot: Global Market

5 Wearable Injectors Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Growing Prevalence of Chronic Diseases
5.2.1.2 Favorable Reimbursement Scenario in Major Markets
5.2.1.3 Technological Advancements and Design Development
5.2.2 Restraints
5.2.2.1 Preference for Alternative Drug Delivery Modes
5.2.3 Opportunities
5.2.3.1 Increasing Demand for Biologics and MABS
5.2.4 Challenges
5.2.4.1 Unfavorable Reimbursement Structure in Developing Countries

6 Wearable Injectors Market By Type
6.1 Introduction
6.2 On-Body Injectors
6.3 Off-Body Injectors

7 Wearable Injectors Market By Therapy
7.1 Introduction
7.2 Immuno-Oncology
7.3 Diabetes
7.4 Cardiovascular Diseases
7.5 Other Therapies

8 Wearable Injectors Market By Region
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 RoAPAC
8.5 Rest of the World

9 Competitive Landscape
9.1 Overview
9.2 Market Share Analysis
9.3 Market Share Analysis, By Therapy
9.3.1 Immuno-Oncology
9.3.2 Amgen
9.3.3 Diabetes
9.3.4 Medtronic
9.3.5 Insulet Corporation
9.3.6 Cardiovascular Diseases
9.3.7 United Therapeutics
9.4 Competitive Scenario
9.4.1 Product Launches and Approvals
9.4.2 Expansions
9.4.3 Agreements, Collaborations, and Partnerships

10 Company Profiles
10.1 Amgen
10.2 Medtronic PLC
10.3 Insulet Corporation
10.4 Ypsomed
10.5 Becton, Dickinson and Company
10.6 Tandem Diabetes Care, Inc.
10.7 United Therapeutics Corporation
10.8 Valeritas, Inc.
10.9 Enable Injections
10.10 Steadymed Therapeutics
10.11 Sensile Medical (A Part of Gerresheimer)

For more information about this report visit https://www.researchandmarkets.com/research/dsqwk8/global_wearable?w=12

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.